Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2025: 11.06%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has an Asset Resilience Ratio of 11.06% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥280.00 Million
≈ $40.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.53 Billion
≈ $370.37 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2022)

This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai Fudan-Zhangjiang Bio-Pharmaceut.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥280.00 Million 11.06%
Total Liquid Assets CN¥280.00 Million 11.06%

Asset Resilience Insights

  • Moderate Liquidity: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has 11.06% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 0.76%
Eris Lifesciences Limited
NSE:ERIS
Drug Manufacturers - Specialty & Generic 0.58%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Lotus Pharmaceutical Co Ltd
TW:1795
Drug Manufacturers - Specialty & Generic 0.49%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Sun Pharma Advanced Research Company Limited
NSE:SPARC
Drug Manufacturers - Specialty & Generic 0.64%

Annual Asset Resilience Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2022)

The table below shows the annual Asset Resilience Ratio data for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 1.12% CN¥33.32 Million
≈ $4.88 Million
CN¥2.98 Billion
≈ $435.48 Million
+1.12pp
2011-12-31 0.00% CN¥11.00K
≈ $1.61K
CN¥358.88 Million
≈ $52.52 Million
-0.04pp
2010-12-31 0.05% CN¥143.00K
≈ $20.93K
CN¥304.15 Million
≈ $44.51 Million
+0.02pp
2006-12-31 0.03% CN¥38.00K
≈ $5.56K
CN¥145.02 Million
≈ $21.22 Million
-0.31pp
2005-12-31 0.33% CN¥475.00K
≈ $69.51K
CN¥142.91 Million
≈ $20.91 Million
--
pp = percentage points

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

SHG:688505 China Drug Manufacturers - Specialty & Generic
Market Cap
$734.50 Million
CN¥5.02 Billion CNY
Market Cap Rank
#10459 Global
#2876 in China
Share Price
CN¥7.14
Change (1 day)
+5.62%
52-Week Range
CN¥6.68 - CN¥11.12
All Time High
CN¥39.80
About

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more